Mesenchymal stromal cells in renal ischemia/reperfusion injury

Ischemia/reperfusion (I/R) injury is an inevitable consequence of organ transplantation and a major determinant of patient and graft survival in kidney transplantation. Renal I/R injury can lead to fibrosis and graft failure. Although the exact sequence of events in the pathophysiology of I/R injury...

Full description

Bibliographic Details
Main Authors: de Vries, Dorottya K., Schaapherder, Alexander F. M., Reinders, Marlies E. J.
Format: Online
Language:English
Published: Frontiers Research Foundation 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387652/
id pubmed-3387652
recordtype oai_dc
spelling pubmed-33876522012-07-10 Mesenchymal stromal cells in renal ischemia/reperfusion injury de Vries, Dorottya K. Schaapherder, Alexander F. M. Reinders, Marlies E. J. Immunology Ischemia/reperfusion (I/R) injury is an inevitable consequence of organ transplantation and a major determinant of patient and graft survival in kidney transplantation. Renal I/R injury can lead to fibrosis and graft failure. Although the exact sequence of events in the pathophysiology of I/R injury remains unknown, the role of inflammation has become increasingly clear. In this perspective, mesenchymal stromal cells (MSCs) are under extensive investigation as potential therapy for I/R injury, since MSCs are able to exert immune regulatory and reparative effects. Various preclinical studies indicate the beneficial effects of MSCs in ameliorating renal injury and accelerating tissue repair. These versatile cells have been shown to migrate to sites of injury and to enhance repair by paracrine mechanisms instead of by differentiating and replacing the injured cells. The first phase I studies of MSCs in human renal I/R injury and kidney transplantation have been started, and results are awaited soon. In this review, preliminary results and opportunities of MSCs in human renal I/R injury are summarized. We might be heading towards a cell-based paradigm shift in the treatment of renal I/R injury. Frontiers Research Foundation 2012-07-02 /pmc/articles/PMC3387652/ /pubmed/22783252 http://dx.doi.org/10.3389/fimmu.2012.00162 Text en Copyright © de Vries, Schaapherder and Reinders. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) , which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author de Vries, Dorottya K.
Schaapherder, Alexander F. M.
Reinders, Marlies E. J.
spellingShingle de Vries, Dorottya K.
Schaapherder, Alexander F. M.
Reinders, Marlies E. J.
Mesenchymal stromal cells in renal ischemia/reperfusion injury
author_facet de Vries, Dorottya K.
Schaapherder, Alexander F. M.
Reinders, Marlies E. J.
author_sort de Vries, Dorottya K.
title Mesenchymal stromal cells in renal ischemia/reperfusion injury
title_short Mesenchymal stromal cells in renal ischemia/reperfusion injury
title_full Mesenchymal stromal cells in renal ischemia/reperfusion injury
title_fullStr Mesenchymal stromal cells in renal ischemia/reperfusion injury
title_full_unstemmed Mesenchymal stromal cells in renal ischemia/reperfusion injury
title_sort mesenchymal stromal cells in renal ischemia/reperfusion injury
description Ischemia/reperfusion (I/R) injury is an inevitable consequence of organ transplantation and a major determinant of patient and graft survival in kidney transplantation. Renal I/R injury can lead to fibrosis and graft failure. Although the exact sequence of events in the pathophysiology of I/R injury remains unknown, the role of inflammation has become increasingly clear. In this perspective, mesenchymal stromal cells (MSCs) are under extensive investigation as potential therapy for I/R injury, since MSCs are able to exert immune regulatory and reparative effects. Various preclinical studies indicate the beneficial effects of MSCs in ameliorating renal injury and accelerating tissue repair. These versatile cells have been shown to migrate to sites of injury and to enhance repair by paracrine mechanisms instead of by differentiating and replacing the injured cells. The first phase I studies of MSCs in human renal I/R injury and kidney transplantation have been started, and results are awaited soon. In this review, preliminary results and opportunities of MSCs in human renal I/R injury are summarized. We might be heading towards a cell-based paradigm shift in the treatment of renal I/R injury.
publisher Frontiers Research Foundation
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387652/
_version_ 1611540464464297984